Company intelligence / Profile preview

Questcor Pharmaceuticals

Anaheim, California, United States

Ownership: Private
Employees: ~250
Development stage: Other

Overview

Questcor’s main product, H.P. Acthar Gel (repository corticotropin injection), was approved and commercialized for multiple indications—including rare, difficult-to-treat autoimmune and inflammatory diseases—prior to the company’s acquisition. Strong revenue growth was driven by dramatic price increases and expanded indications.

Therapeutic areas: ImmunologyNeurologyNephrology
Modalities: Small moleculePeptideSynthetic glucocorticoid corticosteroid (specifically for repository corticotropin)
Industry: Biotech

Partnerships

BioVectra (manufacturing partner)Novartis (for Synacthen rights)

Beyond the preview

Go deeper on Questcor Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Questcor Pharmaceuticals.

Explore the full profile